本报记者 方凌晨 今年以来，权益资产走强带动相关基金表现整体向好。 此外，华泰柏瑞质量精选混合、信澳业绩驱动混合等"翻倍基"也均关注AI方向。中银港股通医药混合发起、永赢医药创新 智选混合发起、长城医药产业精选混合发起式等"翻倍基"则聚焦创新药。 Wind资讯数据显示，截至9月23日，年内净值增长率可统计的7982只（仅统计主代码，下同）权益类基金（股票型+混合 型）中，有7709只基金实现净值增长，占比为96.58%。而去年同期实现净值增长的权益类基金占比仅为18.63%。 截至9月23日，市场上年内净值增长率超100%的权益类"翻倍基"数量达到46只。这些"翻倍基"属于永赢基金、华泰柏瑞基 金、汇添富基金、长城基金、红土创新基金等32家公募机构。 进一步来看，多个产品因布局科技板块取得亮眼成绩。例如，永赢科技智选混合发起A以201.63%的年内净值增长率暂居 榜首，从最新定期报告来看，该基金在今年上半年维持高仓位运作，关注全球云计算产业的投资方向。中航机遇领航混合发起 A、中欧数字经济混合发起A分别以141.81%、136.79%的年内净值增长率位列其后。前者以AI（人工智能）算力为主要方向， 重点配置与 ...

写在文章前的声明：在本文之前的说明：本文中所列的投资信息，只是一个对基金资产净值进行排行的客观描述，并无主观倾向性，也不是投资建议，纯属 娱乐性质。 | 排名 | 代码 | 基金简称 | 2025-09-12 | | 2025-09-11 | | EM = C | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 单位净值3 | 累计净值$ | 单位净值8 | 累计净值3 | | | 1 | 009645 | 东方阿尔法优势产业混合C | 2.0172 | 2.0172 | 1.9297 | 1.9297 | 0.08 | | 2 | 009644 | 东方阿尔法优势产业混合A | 2.0702 | 2.0702 | 1.9805 | 1.9805 | 0.08 | | 3 | 021793 | 华泰保兴产业升级混合发起C | 1.3199 | 1.3199 | 1.2669 | 1.2669 | 0.05 | | 4 | 021792 | 华泰保兴产业升级混合发起A | 1.3230 | 1.3230 | 1.2699 | 1.2699 | ...

Group 1 - The article provides a ranking of open-end funds based on their net asset value growth over a 10-day period, highlighting the top and bottom performers [2][4][6] - The top 10 funds with the highest net value growth include Anxin Innovation Pioneer Mixed Fund A, Anxin Innovation Pioneer Mixed Fund C, and Huian Growth Preferred Mixed Fund A, among others [2][4] - The bottom 10 funds with the lowest net value growth include Huaxia Industry Selection Mixed Fund C and HSBC Jintrust Era Pioneer Mixed Fund A, showing a decline in their net values [4][6] Group 2 - The article notes that as of September 10, 2025, a total of 28,679 funds have updated their net values, indicating a significant level of market activity [3] - The Shanghai Composite Index showed slight fluctuations, while the ChiNext Index experienced a rebound, with a total trading volume of 2 trillion yuan [6] - Leading sectors included telecommunications, tourism, and the internet, all showing growth of over 2%, while sectors like electrical equipment and chemicals faced declines [6] Group 3 - The article mentions that the fund with the fastest net value growth is Anxin Innovation Pioneer Mixed Fund A, which aligns with the trend of increasing interest in technology and innovation sectors [6] - The article also highlights the concentration of holdings in certain funds, with Anxin Innovation Pioneer Mixed Fund having a concentration of 62.87% in its top ten holdings, indicating a focused investment strategy [9] - The performance of individual stocks within these funds, such as the significant gains in companies like Zhongxin International and Shenghong Technology, reflects the underlying strength of the technology sector [9]

Group 1 - Core viewpoint: 联特科技 (301205.SZ) reported its 2025 semi-annual results, revealing significant institutional investor interest with 21 institutions holding a total of 23.56 million shares, representing 18.16% of the total share capital [1] - The top ten institutional investors collectively hold 18.02% of the shares, with a decrease of 3.94 percentage points compared to the previous quarter [1] - The report indicates a notable presence of various investment firms, including Wuhan Tongchuang and Shenzhen Tongchuang, among the top shareholders [1] Group 2 - In the public fund sector, there was a slight increase in holdings from one public fund, 南方中证1000ETF, while 12 new public funds were disclosed compared to the previous quarter [2] - The newly disclosed public funds include 中航机遇领航混合发起A and 安信创新先锋混合发起A, among others [2] - One foreign institution, 香港中央结算有限公司, was newly disclosed in the current period, indicating ongoing foreign interest [2]

Group 1 - The core viewpoint of the news is that Aopumai is experiencing rapid growth in cell culture medium revenue driven by large orders and ongoing commercialization projects, with new products like transfection reagents and agarose showing promising growth despite a small base [1] - Aopumai's overseas cell culture medium business has seen a remarkable growth rate of 34.92%, primarily contributed by large clients [1] - The overall gross margin for the company is 56.84%, while the gross margin for cell culture product sales is 71.91%, indicating no significant difference in gross margins domestically and internationally when excluding CDMO business [1] Group 2 - Zhonghang Fund, established in 2016, has an asset management scale of 42.229 billion yuan, ranking 90th out of 210 in total public funds [2] - The best-performing public fund product in the past year under Zhonghang Fund is the Zhonghang Opportunity Leading Mixed Fund A, with a latest net value of 2.63 and a growth of 172.64% over the past year [2]